| P/E (FY) | 24.0 | Sales (TTM) | ₩706.74B |
| Earnings (TTM) | ₩266.95B | ROE | 39.28% |
| Net Margin | 37.77% | ROIC | 49.76% |
| Debt / Equity | 0.00 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 42.12% |
| Market Cap | $4.39B | Trading Days | 1428 |
| 52W High | 144100.00 |
| 52W Low | 74000.00 |
| % Off High | −43.16% |
| YTD | −34.27% | 1Y | −19.07% |
| 3Y | −2.50% | 5Y | −32.87% |
| Since incept. (ann.) | −6.98% |
| Ann. Volatility (1Y) | 52.05% | Ann. Volatility (3Y) | 47.50% |
| Sharpe (1Y) | −0.19 | Sharpe (3Y) | 0.21 |
| Max Drawdown (1Y) | −46.98% | Max Drawdown (3Y) | −46.98% |
| Beta (3Y, vs SPY) | 0.53 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| NVST | Envista Holdings Corp | $4.39B | 96.3 |
| CAI | Caris Life Sciences, Inc. | $4.41B | — |
| LFST | LifeStance Health Group, Inc. | $4.36B | — |
| VCYT | VERACYTE, INC. | $4.44B | 67.9 |
| EWTX | Edgewise Therapeutics, Inc. | $4.34B | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $4.45B | 11.3 |
| LIVN | LivaNova PLC | $4.51B | — |
| DFTX | Definium Therapeutics, Inc. | $4.58B | — |
| CRSP | CRISPR Therapeutics AG | $4.59B | — |
| CON | Concentra Group Holdings Parent, Inc. | $4.18B | 25.1 |
| MANE | Veradermics, Inc | $4.66B | — |
| ICUI | ICU MEDICAL INC/DE | $4.14B | 5525.8 |
